title: [Oncological results of renal cancer with inferior vena cava thrombosis after nephrectomy].
abstract: OBJECTIVE
  The objective of this study was to evaluate survival and risk of recurrence in patients undergoing nephrectomy with resection of inferior vena cava tumour thrombus in our department.
  
  
  METHODS
  From June 1991 to March 2003, 40 patients underwent radical nephrectomy with resection of inferior vena cava tumour thrombus. The upper limit of the tumour thrombus was below the hepatic veins in 21 cases (52.5%) and above the hepatic veins in 19 cases (47.5%), with thrombus in the right atrium in 6 cases (15%). Cardiopulmonary bypass (CPB) was used in 12 patients (30%)
  
  
  RESULTS
  With a mean follow-up of 28.5 +/- 36.8 months (range: 0-150), 22 patients (55%) have died. The 2- and 5-year overall survival rates were 45.2% and 38. 7%, respectively. Local and/or metastatic recurrence was observed in 28 patients (70%) after a mean interval of 18 +/- 22.9 months (range: 1-104). Patients with tumour thrombus derived from the left kidney had a higher local recurrence rate than patients with thrombus derived from the right kidney (p = 0.0194). The 2- and 5-year recurrence-free survival rates were 28.3% and 8.9%, respectively. Only stage pN had a statistically significant prognostic value on overall survival, but not on recurrence-free survival. At the end of the study, only 1 patient (2.5%) can be considered to be cured with no disease progression with a sufficient follow-up (52 months) after nephrectomy.
  
  
  CONCLUSIONS
  Nephrectomy with resection of tumour thrombus from the inferior vena cava provides a gain in terms of medium-term survival, but the majority of patients are not cured by this major surgery. Only lymph node status has a prognostic value.
authors.affiliation: Service d'Urologie, Hôtel Dieu, Nantes, France. jrigaud@chu-nantes.fr
authors.forename: Jérôme
authors.initials: J
authors.lastname: Rigaud
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Hétet
authors.forename: Guillaume
authors.initials: G
authors.lastname: Braud
authors.forename: Simon
authors.initials: S
authors.lastname: Battisti
authors.forename: Loïc
authors.initials: L
authors.lastname: Le Normand
authors.forename: Pascal
authors.initials: P
authors.lastname: Glemain
authors.forename: Georges
authors.initials: G
authors.lastname: Karam
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouchot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009360:Neoplastic Cells, Circulating; D009392:Nephrectomy; D011379:Prognosis; D014682:Vena Cava, Inferior